Nijmegen, Netherlands-based global drug discovery company, Symeres acquired Exemplify Biopharma. The company announced the acquisition on October 25, 2022. However, the company did not disclose the amount of the purchase. Keensight Capital worked with the management teams of both companies to facilitate the acquisition.
Exemplify BioPharma is a U.S.A-based CRO that provides integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners.
Purpose of acquisition by Symeres
This acquisition further strengthens Symeres’ strategic foothold in the U.S.A. The company generates about 50% of its revenues from the nation. Symeres earlier acquired Organix Inc.
What the Symeres official has to say
Dr Eelco Ebbers, Co-founder and CEO of Symeres, said, “We are pleased to welcome Exemplify BioPharma into the group. Exemplify has an excellent track record of supporting the development needs of North American biotech companies through their experience and outstanding laboratory-based science. This acquisition, following the addition of Organix earlier this year and our investment plans for all of our R&D facilities, is a further tangible demonstration of Symeres’ strategy of building a leading mid-sized transatlantic pharmaceutical R&D service provider for our clients around the world.”
What the Exemplify Biopharma CEO has to say
Yadan Chen, CEO of Exemplify BioPharma, further added, “We are proud to see Exemplify BioPharma’s scientific expertise and strategic location in North America recognized and become part of the Symeres family. Symeres is a trusted partner that shares our values and business philosophy of strong customer focus. Exemplify BioPharma’s recent move to our new and larger state-of-the-art facility, and the combination with a global business like Symeres will allow us to better serve our clients under one roof. We look forward to accelerating our growth together.”
What Keensight Capital has to say
In addition, Amit Karna, Partner at Keensight Capital, said, “Following the recent acquisition of Organix in the Boston area, the addition of Exemplify BioPharma in New Jersey marks another milestone in Symeres’ strategy to build a truly transatlantic business, serving the biopharma industry globally. The scientific and cultural fit of Exemplify BioPharma within the group is excellent. Keensight Capital is delighted to support Symeres in this exciting acquisition.”
About the company
Dr Eelco Ebbers founded the company in 2015. Symeres is a mid-sized transatlantic Contract Research Organization for drug discovery and development needs. The company boasts 600 employees operating from 7 sites in the Netherlands, the Czech Republic, Finland, and the US.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
